<DOC>
	<DOCNO>NCT00103857</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness investigational drug patient Type 2 Diabetes Mellitus ( T2DM ) ( specific type diabetes ) .</brief_summary>
	<brief_title>MK0431 ( Sitagliptin ) Metformin Co-Administration Factorial Study Patients With Type 2 Diabetes Mellitus ( 0431-036 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>54Week Base Study : Patients age 18 78 Type 2 Diabetes Mellitus ( specific type diabetes ) 50Week Extension Study : Patients complete 54week base study eligible enter 50week extension study Patients Type 2 Diabetes Mellitus ( specific type diabetes )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>